Abstract
The serum fatty acid composition has been investigated in seven patients with slowly progressive multiple sclerosis and in five control individuals. The serum level of tymnodonic (C20:5 ω-3) and clupadonic acid (C22:6 ω-3) has been shown to be normal in multiple sclerosis patients. Before diet supplementation with Maxepa there was significant decrease of linolenic (C18:3) and eicosanoic (C20:1) acids, as well as an increase of palmitic acid (C 16:0) in sera of MS patients. The variation in the serum fatty acid pattern in MS patients after 1 week diet supplementation with Maxepa has been measured for the first time. There was significant increase in serum clupadonic, tymnodonic and arachi-donic acid (C 20:4 ω-6) in MS patients who have been given Maxepa. Linolenic (C 18:3) and eicosanoic (C20:1) acids remained not supplemented and palmitic acid (C16:0) was still increased. It has been suggested that the diet supplementation in slowly progressive multiple sclerosis should consist of both ω-3 and ω-6 polyunsaturated fatty acids.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
